• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

VARENICLINE Drug Record

  • Summary
  • Interactions
  • Claims
  • VARENICLINE chembl:CHEMBL1396 Approved

    Alternate Names:

    CHANTIX
    CP-526555
    CP-526,555
    VARENICLINE

    Drug Info:

    Drug Class smoking-cessation agent
    Year of Approval 2006
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications smoking-cessation agent
    (1 More Sources)

    Publications:

    Rollema et al., 2007, Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation., Trends Pharmacol. Sci.
    Steensland et al., 2007, Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking., Proc. Natl. Acad. Sci. U.S.A.
    McColl et al., 2008, Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers., Clin. Pharmacol. Ther.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Nakamura et al., 2007, Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers., Clin Ther
    Rocha Santos J et al., 2015, CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy., Front Genet
    Mihalak et al., 2006, Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors., Mol. Pharmacol.
    Niaura R et al., 2006, Varenicline., Nat Rev Drug Discov
    Lerman C et al., 2015, Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial., Lancet Respir Med
  • VARENICLINE   HYKK

    Interaction Score: 8.83

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VARENICLINE   CHRNA4

    Interaction Score: 2.09

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)

    Interaction Info:
    Trial Name varenicline, CP-526
    Novel drug target Established target

    PMIDs:
    17573127 17626178 18288085 11752352 17692720 25774163


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • VARENICLINE   CHRNB2

    Interaction Score: 1.1

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:
    Trial Name varenicline, CP-526
    Novel drug target Established target

    PMIDs:
    16883648


    Sources:
    TdgClinicalTrial

  • VARENICLINE   CHRNA3

    Interaction Score: 1.1

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)

    Interaction Info:
    Trial Name varenicline, CP-526
    Novel drug target Established target

    PMIDs:
    16766716


    Sources:
    TdgClinicalTrial

  • VARENICLINE   CYP2A6

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25588294


    Sources:
    PharmGKB

  • VARENICLINE   CHRNA7

    Interaction Score: 0.72

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name varenicline, CP-526
    Novel drug target Established target

    PMIDs:
    16766716


    Sources:
    TdgClinicalTrial TEND

  • VARENICLINE   CHRNB4

    Interaction Score: 0.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name varenicline, CP-526
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • TEND: VARENICLINE

    • Version: 01-August-2011

    Alternate Names:
    VARENICLINE Primary Drug Name

    Drug Info:
    Year of Approval 2006
    Drug Class smoking-cessation agent

    Publications:

  • TdgClinicalTrial: VARENICLINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications smoking-cessation agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: varenicline

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Rocha Santos J et al., 2015, CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy., Front Genet
    Lerman C et al., 2015, Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial., Lancet Respir Med

  • TTD: Varenicline

    • Version: 2020.06.01

    Alternate Names:
    D0LM4A TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1396

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21